Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-04-11 Sale |
2024-04-15 7:06 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
30,000 | $25.04 | $751,332 | 1,347,585 (Indirect Direct) |
View |
| 2024-04-11 Sale |
2024-04-15 7:05 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
47,709 | $25.04 | $1,194,700 | 1,477,428 (Indirect Direct) |
View |
| 2024-04-11 Sale |
2024-04-15 7:04 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
14,000 | $24.72 | $346,149 | 225,370 (Direct) |
View |
| 2024-04-11 Sale |
2024-04-15 7:03 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
6,964 | $24.11 | $167,888 | 203,129 (Indirect Direct) |
View |
| 2024-04-11 Sale |
2024-04-15 7:02 pm |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
20,000 | $25.07 | $501,478 | 267,084 (Direct) |
View |
| 2024-04-10 Sale |
2024-04-12 6:23 pm |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
67,000 | $23.36 | $1,564,812 | 146,903 (Direct) |
View |
| 2024-04-08 Sale |
2024-04-10 8:35 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
4,875 | $18.6 | $90,687 | 396,624 (Indirect Direct) |
View |
| 2024-04-04 Sale |
2024-04-08 8:40 pm |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
3,485 | $19.15 | $66,729 | 84,761 (Direct) |
View |
| 2024-04-01 Sale |
2024-04-03 9:32 pm |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
3,237 | $19.08 | $61,758 | 104,674 (Direct) |
View |
| 2024-04-01 Sale |
2024-04-03 9:30 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $18.6 | $223,146 | 1,377,585 (Indirect Direct) |
View |
| 2024-03-27 Sale |
2024-03-29 5:59 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $18.25 | $59,302 | 239,370 (Direct) |
View |
| 2024-03-25 Sale |
2024-03-27 5:03 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $17.56 | $210,661 | 1,525,137 (Indirect Direct) |
View |
| 2024-03-20 Sale |
2024-03-22 7:46 pm |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
13,278 | $19.16 | $254,462 | 41,912 (Direct) |
View |
| 2024-03-19 Sale |
2024-03-21 6:41 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $14.5 | $18,419 | 210,093 (Indirect Direct) |
View |
| 2024-03-06 Sale |
2024-03-08 7:52 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
4,875 | $15.64 | $76,239 | 401,499 (Indirect Direct) |
View |
| 2024-02-29 Sale |
2024-03-04 5:55 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $16.42 | $197,006 | 1,389,585 (Indirect Direct) |
View |
| 2024-02-27 Sale |
2024-02-29 5:27 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $16.97 | $55,163 | 242,620 (Direct) |
View |
| 2024-02-26 Sale |
2024-02-28 5:14 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $16.89 | $202,653 | 1,537,137 (Indirect Direct) |
View |
| 2024-02-15 Sale |
2024-02-20 7:41 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $17.42 | $22,117 | 211,363 (Indirect Direct) |
View |
| 2024-02-14 Sale |
2024-02-16 4:15 pm |
Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner |
825,000 | $14.9 | $12,292,500 | 635,341 (Indirect) |
View |
| 2024-02-06 Sale |
2024-02-08 8:47 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
4,875 | $15.11 | $73,658 | 406,374 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-04-11 Exercise |
2024-04-15 7:06 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
30,000 | $1.12 | 1,347,585 (Direct) |
View |
| 2024-04-11 Exercise |
2024-04-15 7:06 pm |
N/A 2030-06-16 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
30,000 | $0 | 1,347,585 (Direct) |
View |
| 2024-04-11 Exercise |
2024-04-15 7:05 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
47,709 | $1.12 | 1,477,428 (Direct) |
View |
| 2024-04-11 Exercise |
2024-04-15 7:05 pm |
N/A 2030-06-16 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
47,709 | $0 | 1,477,428 (Direct) |
View |
| 2024-04-11 Exercise |
2024-04-15 7:04 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
14,000 | $2.48 | 225,370 (Direct) |
View |
| 2024-04-11 Exercise |
2024-04-15 7:04 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
14,000 | $0 | 225,370 (Direct) |
View |
| 2024-04-11 Exercise |
2024-04-15 7:02 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
20,000 | $2.48 | 267,084 (Direct) |
View |
| 2024-04-11 Exercise |
2024-04-15 7:02 pm |
N/A 2031-06-17 |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
20,000 | $0 | 267,084 (Direct) |
View |
| 2024-04-10 Exercise |
2024-04-12 6:23 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
62,420 | $12.6 | 146,903 (Direct) |
View |
| 2024-04-10 Exercise |
2024-04-12 6:23 pm |
N/A 2028-10-19 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
67,000 | $0 | 146,903 (Direct) |
View |
| 2024-04-11 Exercise |
2024-04-12 6:23 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
4,580 | $19.68 | 146,903 (Direct) |
View |
| 2024-04-08 Option Award |
2024-04-10 8:39 pm |
N/A 2034-04-08 |
Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director |
37,882 | $0 | 37,882 (Direct) |
View |
Ownership |
2024-04-10 8:37 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director |
0 | $0 | 65,625 (Direct) |
View |
| 2024-04-04 Exercise |
2024-04-08 8:40 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
3,485 | $12.6 | 84,761 (Direct) |
View |
| 2024-04-04 Exercise |
2024-04-08 8:40 pm |
N/A 2028-10-19 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
3,485 | $0 | 84,761 (Direct) |
View |
| 2024-04-01 Exercise |
2024-04-03 9:32 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
3,143 | $5.52 | 104,674 (Direct) |
View |
| 2024-04-01 Exercise |
2024-04-03 9:32 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
94 | $12.6 | 104,674 (Direct) |
View |
| 2024-04-01 Exercise |
2024-04-03 9:32 pm |
N/A 2028-10-19 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
3,237 | $0 | 104,674 (Direct) |
View |
| 2024-04-01 Exercise |
2024-04-03 9:30 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $1.12 | 1,377,585 (Direct) |
View |
| 2024-04-01 Exercise |
2024-04-03 9:30 pm |
N/A 2030-06-16 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $0 | 1,377,585 (Direct) |
View |
| 2024-03-27 Exercise |
2024-03-29 5:59 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 239,370 (Direct) |
View |
| 2024-03-27 Exercise |
2024-03-29 5:59 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 239,370 (Direct) |
View |
| 2024-03-25 Exercise |
2024-03-27 5:03 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $1.12 | 1,525,137 (Direct) |
View |
| 2024-03-25 Exercise |
2024-03-27 5:03 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $0 | 1,525,137 (Direct) |
View |
| 2024-03-20 Exercise |
2024-03-22 7:46 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
13,278 | $5.52 | 41,912 (Direct) |
View |
| 2024-03-20 Exercise |
2024-03-22 7:46 pm |
N/A 2032-01-27 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
13,278 | $0 | 41,912 (Direct) |
View |
| 2024-02-29 Exercise |
2024-03-04 5:55 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $1.12 | 1,389,585 (Direct) |
View |
| 2024-02-29 Exercise |
2024-03-04 5:55 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $0 | 1,389,585 (Direct) |
View |
| 2024-02-27 Exercise |
2024-02-29 5:27 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 242,620 (Direct) |
View |
| 2024-02-27 Exercise |
2024-02-29 5:27 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 242,620 (Direct) |
View |
| 2024-02-26 Exercise |
2024-02-28 5:14 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $1.12 | 1,537,137 (Direct) |
View |
| 2024-02-26 Exercise |
2024-02-28 5:14 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $0 | 1,537,137 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:35 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director |
23,364 | $0 | 23,364 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:32 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
29,205 | $0 | 29,205 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:30 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
23,364 | $0 | 23,364 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:27 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director |
23,364 | $0 | 23,364 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:26 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Bauer Jake Director |
23,364 | $0 | 23,364 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:24 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
23,364 | $0 | 23,364 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 9:04 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director |
16,835 | $0 | 16,835 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 9:02 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
185,000 | $0 | 185,000 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 9:00 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
185,000 | $0 | 185,000 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:56 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
410,000 | $0 | 410,000 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:54 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
185,000 | $0 | 185,000 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:52 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
21,043 | $0 | 21,043 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:50 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
16,835 | $0 | 16,835 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:48 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director |
16,835 | $0 | 16,835 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:46 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
185,000 | $0 | 185,000 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:44 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Bauer Jake Director |
16,835 | $0 | 16,835 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:41 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
16,835 | $0 | 16,835 (Direct) |
View |